Advertisement
Advertisement
U.S. markets close in 2 hours 55 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Phathom Pharmaceuticals, Inc. (PHAT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.72+1.43 (+19.62%)
As of 01:05PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close7.29
Open7.28
Bid8.75 x 800
Ask8.82 x 800
Day's Range7.18 - 9.20
52 Week Range6.09 - 37.17
Volume2,616,319
Avg. Volume277,524
Market Cap341.608M
Beta (5Y Monthly)0.75
PE Ratio (TTM)N/A
EPS (TTM)-4.00
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est39.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PHAT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Phathom Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 11/09/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • GlobeNewswire

    Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates

    Erosive Esophagitis (EE) New Drug Application (NDA) accepted by U.S. Food and Drug Administration (FDA) with Prescription Drug User Fee Act (PDUFA) action date of January 11, 2023; if approved, targeting U.S. launch in Q1 2023 VOQUEZNA DUAL and TRIPLE PAK approved by FDA for treatment of H. pylori infection on May 3, 2022 Initial testing for nitrosamines revealed trace levels in vonoprazan commercial drug product; working with FDA to make VOQUEZNA DUAL and TRIPLE PAK available to patients as soo

  • GlobeNewswire

    Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

    FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of the management team will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:30 p.m. ET. Company management will also participate in one-on-one meetings during the conference which runs

  • GlobeNewswire

    Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis

    FLORHAM PARK, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for vonoprazan as a treatment for adults for the healing of all grades of erosive esophagitis (EE) and relief of heartburn, and maintenance of healing of all

Advertisement
Advertisement